Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment

BACKGROUND: Ranibizumab (Lucentis®) is a Fab-antibody fragment developed from Bevacizumab, a full-length anti-VEGF antibody. Both compounds are used for treating age-related macular degeneration (AMD). The influence of bevacizumab and ranibizumab on genes involved in signal transduction and cell sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Golan, Shani, Entin-Meer, Michal, Semo, Yonathan, Maysel-Auslender, Sofia, Mezad-Koursh, Daphna, Keren, Gad, Loewenstein, Anat, Barak, Adiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167513/
https://www.ncbi.nlm.nih.gov/pubmed/25201034
http://dx.doi.org/10.1186/1756-0500-7-617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167513/
https://www.ncbi.nlm.nih.gov/pubmed/25201034
http://dx.doi.org/10.1186/1756-0500-7-617

Ejemplares similares